Update to contractual arrangements between AstraZeneca, Swed

AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the... | April 12, 2023

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Adrian Kemp , Company On Twitter Astrazeneca , Alliance Revenue , Nasdaq , Astrazeneca , Centers For Disease , Sanofi Alliance , European Commission , Regulatory Agency , Investor Relations Team , Kingdom Medicines , Collaboration Revenue , Rare Diseases , Disease Control , Swedish Orphan Biovitrum Ab Publ Stock Exchange , News , Information , Press Release , Swedish , Orphan , Iovitrum , Tb , End , Sanofi , Wave , Pdated , Simplified , Their , Contractual , Arrangements , Elating , O , The , Development , Commercialisation , F , Nirsevimab , N , Iven Sobi Se0000872095 ,